TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04963062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser with Moses lasers
Description: The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser with thulium lasers
Description: The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
Study: NCT05865418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded high intensity training
Description: Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity circuit training (HICT)
Description: Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
Study: NCT06383013

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BB-101
Description: Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BB-101
Description: Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BB-101
Description: Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
Study: NCT06096636

Intervention type: OTHER
Intervention: Study participants
Description: Participants will complete study survey and dietary assessment.
Study: NCT06282406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
Study: NCT04792723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual aspirin
Description: Vita Green Health Products sublingual aspirin 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral aspirin
Description: Synco (HK) oral aspirin 80mg tablet
Study: NCT05823662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DJ stent
Description: A 5 Fr DJ stent will be inserted and then removed after three weeks.
Study: NCT06323473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Maitake Prothera
Description: Mushroom extract; liquid
Study: NCT06526169

Intervention type: OTHER
Intervention: Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection
Description: Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.

Intervention type: OTHER
Intervention: Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection
Description: Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.

Intervention type: OTHER
Intervention: Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection
Description: Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.
Study: NCT06567860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Fluzone vaccine
Description: Fluzone vaccine administered in both May-June and in September-October for each participant.
Study: NCT05453201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long COVID Coping and Recovery (LCCR) Intervention
Description: Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
Study: NCT06461273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine Program
Description: Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Groceries
Description: Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips.
Study: NCT06311175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Tracking Prescription
Description: Dietary tracking prescriptions to follow during a digital weight loss intervention.
Study: NCT06443281

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental pain paradigms
Description: Temporal summation of pain, conditioned pain modulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental pain paradigms
Description: Temporal summation of pain, conditioned pain modulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Thermal and mechanical sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Thermal and mechanical sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Thermal and mechanical sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Thermal and mechanical sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical pain phenotype
Description: Pain drawings, plus and minus signs of pain

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical pain phenotype
Description: Pain drawings, plus and minus signs of pain
Study: NCT06004115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
Study: NCT06649747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281
Description: A small molecule, orally available

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281
Description: A small molecule, orally available

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281
Description: A small molecule, orally available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AFA-281
Description: A small molecule, orally available
Study: NCT06232122

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46
Description: Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of one dosage of 5-10mCi 18F-FDG
Study: NCT04977999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both arms/conditions use varying forms of exercise as the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both arms/conditions use varying forms of exercise as the intervention.
Study: NCT05384743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Monotherapy
Description: Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
Study: NCT04542291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin will be provided for this trial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOSENSE meters
Description: -Being used in this trial to evaluate utility for assessing breath ketones
Study: NCT05111834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised resistance training plus nutritional endorsement
Description: resistance training 2x per week, nutritional endorsement/therapy based on individual needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional endorsement
Description: nutritional endorsement/therapy based on individual needs
Study: NCT04630340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STEADES-2
Description: In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
Study: NCT06663046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single dose injection of certain dose of UWD-00B
Description: Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
Study: NCT06658132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.
Description: Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
Study: NCT05016128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline is used for control
Study: NCT06598007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
Study: NCT05823662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
Study: NCT05855746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.
Study: NCT05725564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST (Functional Activity Strength Training)
Description: Daily exercise intervention including functional resistance exercises and personalized coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST (Functional Activity Strength Training)
Description: Daily exercise intervention including functional resistance exercises and personalized coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Band Together
Description: 3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Band Together
Description: 3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Change Technique
Description: Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Change Technique
Description: Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
Study: NCT06465459

Intervention type: PROCEDURE
Intervention: LAMBRE device implantation
Description: LAMBRE device implantation
Study: NCT06396806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green fluorescence imaging lymphatic tracing
Description: At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
Study: NCT05772104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shugan Jieyu Capsules
Description: Oral, 4 Capsules, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shugan Jieyu Capsules Placebo
Description: Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID
Study: NCT05984277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed
Study: NCT06529822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic long peptide personalized cancer vaccine
Description: Neoantigen vaccines will be provided on a patient-specific basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Poly-ICLC will be supplied by Oncovir, Inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera assay
Description: Signatera is a clinically validated, personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS) based clinical trial assay targeting 16 tumor-specific mutations. It is intended for the detection of ctDNA isolated from anticoagulated peripheral whole blood from post-surgical patients previously diagnosed with localized or advanced solid tumors to aid physician assessment and treatment decision-making, together with other clinical factors
Study: NCT06346067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naporafenib
Description: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naporafenib
Description: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naporafenib
Description: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine IV - Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Study: NCT06253507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47
Description: Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg.
Study: NCT04996069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crest Whitening Emulsions
Description: Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.